The pharmacology of TPCs includes established CaV antagonists (Figure 2), that are already in use to treat cardiovascular disorders, including hypertension, acute coronary syndrome, and AMI, and has been recently expanded by novel FDA-approved drugs (Figure 2), such as dopamine antagonists and selective estrogen receptor modulators. The gene discussed is ESR1; the disease is hypertensive disorder.